'Advancing the science and practice of pharmaceutical medicine for the benefit of the public'
Aims of the Faculty
The Faculty is a professional membership organisation with approximately 1,400 members who are practising or retired pharmaceutical physicians or those with a professional interest in the speciality. Approximately 35% of Faculty members are based outside the United Kingdom.
Pharmaceutical medicine is a medical specialty concerned with the discovery, development, evaluation, licensing and monitoring of medicines and the medical aspects of their marketing.
The Faculty of Pharmaceutical Medicine's mission is to advance the science and practice of pharmaceutical medicine by working to develop and maintain competence, ethics and integrity and the highest professional standards in the specialty for the benefit of the public. The Faculty seeks, through its activities, to bring about an improvement in the health of the public.
The Faculty's Ethics Report and Guiding Principles was revised in 2005 and published in the International Journal of Clinical Practice in 2006. The articles and further information about the work of the Ethical Issues Committee can be found here.
February 2009
Innovating for health: Patients, physicians, the pharmaceutical industry and the NHS
Press release from the Royal College of Physicians in connection with the launch of their report 'Innovating for health: Patients, physicians, the pharmaceutical industry and the NHS.' This report follows a review by a multi-sector working party which included input from the Faculty. Further information is available here
The Academy of Medical Royal Colleges issued a Consensus Statement on UK Clinical Research in the 7 February 2009 edition of The Lancet. The Academy urged thegovernment to work in partnership with the medical profession and pharmaceutical industry to ensure that patients are able to access innovative, life-enhancing medicines and other interventions. It highlights the need to encourage and support NHS clinicians, managers and patients to become involved with clinical trials and associated research, and considers that only by working collaboratively and retaining long-term investment will we ensure the UK remains an attractive location for future clinical trials with the consequent benefits to patients.
